← Back to Search

Aromatase Inhibitor

Letrozole for Breast Cancer

Phase < 1
Waitlist Available
Led By Andrew Brenner, MD, PhD
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Study Summary

This trial will assess the impact of dietary omega 3 free fatty acids and/or letrozole on obese, postmenopausal breast cancer patients.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in levels of aromatase target gene.
Change in serum levels of PGE2 (prostaglandin E2).

Trial Design

3Treatment groups
Active Control
Group I: LetrozoleActive Control1 Intervention
Letrozole 2.5 mg by mouth daily for 30 days.
Group II: Fish OilActive Control1 Intervention
Fish oil 2700 mg by mouth daily for 30 days.
Group III: Letrozole and Fish OilActive Control2 Interventions
Letrozole 2.5 mg and Fish oil 2700 mg by mouth daily for 30 days.

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
455 Previous Clinical Trials
91,384 Total Patients Enrolled
14 Trials studying Breast Cancer
1,516 Patients Enrolled for Breast Cancer
Andrew Brenner, MD, PhDPrincipal InvestigatorPrincipal Investigator
1 Previous Clinical Trials
26 Total Patients Enrolled
~3 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top